ABSTRACT: Spinal cord injury (SCI) is global health concern. The effective strategies for SCI are relevant to the improvement on nerve regeneration microenvironment. Vascular endothelial growth factor (VEGF) is an important cytokine for inducing angiogenesis and accelerating nerve system function recovery from injury. We proposed that VEGF could improve nerve regeneration in SCI. However, an uncontrolled delivery system target to injury site not only decreases the therapeutic efficacy but also increases the risk of tumor information. We implanted collagen scaffold (CS) targeted with a constructed protein, collagen-binding VEGF (CBD-VEGF), to bridge transected spine cord gap in a rat transected SCI model. Functional and histological examinations were conducted to assess the repair capacity of the delivery system CS/CBD-VEGF. The results indicated that the implantation of CS/CBD-VEGF into the model rats improved the survival rate and exerted beneficial effect on functional recovery. The controlled intervention improved the microenvironment, guided axon growth, and promoted neovascularization at the injury site. Therefore, the delivery system with stable binding of VEGF potentially provides a better therapeutic option for SCI. ß
In recent years, post-traumatic spinal cord injuries have become a global health concern. The clinical manifestations of the sections below the limbs that have been damaged after the injury are often result in varying degrees of dysfunction. After spinal cord injury (SCI), apart from axon injury factors leading to its destruction and secondary pathophysiological changes causing irreversible damage of spinal cord structure and function, such as local vascular disorders and immune and inflammatory responses inducing the release of free radicals and lipid peroxidation, 1-2 scarring lesions limit further axonal regeneration. 3 Currently, nerve repair and functional recovery after SCI are still plagued by problems in clinical medicine. In recent years, scaffolds and cytokines were used for neural repair and functional recovery. 4 Collagen is an important structural protein in human tissues. It is derived from the extracellular matrix. It accounts for approximately 30% of the total protein in the human body. Due to its low antigenicity and immunogenicity and excellent biocompatibility and biodegradability, collagen scaffold is widely used in nerve regeneration. 5 But simple application of collagen scaffold in the treatment of spinal cord injury is far from enough. The cytokines play important roles in neural repair and functional recovery. They are benefit to the local microenvironment.
VEGF was demonstrated to be a potent neurotrophic factor which has a protective effect for spinal cord injury. The activation of VEGF can increase local vascular density, restore blood supply, promote axonal survival, as well as pain reduction and functional recovery after injury. 6 However, VEGF is readily biodegradable and spreading to the surrounding areas, and its halflife is too short. Therefore, simple delivery cannot maintain a stable local concentration of the drug used and sustain its activity at the target site for a sufficient period of time. 7 Studies showed that uncontrolled expression of VEGF increases the risk of tumor formation at the delivery site. 8 So it is necessary to find a carrier that can be stable and sustained release of VEGF.
To increase the adhesion of VEGF on collagen, we previously produced a collagen-binding VEGF (CBD-VEGF) by fusing a heptapeptide (TKKTLRT) to VEGF through recombinant DNA technology. 9 It has been demonstrated that the fusion protein could bind stably to collagen without biological activity loss. 10 Then, a delivery system was developed by loading CBD-VEGF on the collagen scaffold. In this work, we implanted a CS/CBD-VEGF delivery system into the completely excised spinal cord of model rats to bridge the transected nerve stumps. Morphological, histological, and functional assessments were performed to evaluate the outcomes.
Surgical Procedure of Transected Spinal Cord Injury Model
The experimental protocols were licensed by the Animal Ethic Committees of Soochow University (Approval No. SU 2014-0030) and all the procedures were followed the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH).
Adult male Sprague-Dawley (SD) rats (Laboratory animal of the Soochow University, Suzhou, China) with a body weight of 200-230 g were used for the surgical procedures. The rats were randomized into a sham-operated group (laminectomy without transection), a control-operated group (transection without grafting), and two grafted groups with CS or CS/ CBD-VEGF. There were 20 rats in each group . The rats were anesthetized with sodium pentobarbital (50 mg/kg body weight). Before the T9 full-cut spinal cord column model was made, the T9 vertebral body was exposed by incising the skin and splitting the muscle tissue. Laminectomy was performed at T9 to expose the spinal cord, and then the spinal cord was transected, and a 3-mm column was removed at T9. The extent of the lesion was measured by a 3-mm width scrip (Fig. 1) . Then, the spinal cord defect was bridged by: (i) a bundle of CS with dimensions of 4 mm Â 2 mm Â3 mm; (ii) a bundle of CS with dimensions of 4 mm Â 2 mm Â 3 mm. CS fused with CBD-VEGF (0.5 nmol/5ml/bundle).
14 Further, the muscle layers and skin were sutured individually.
The Survival of SCI After surgery, the animals in the four groups were kept in the cages and fed routinely. They were taken the same nursing measures. Antibiotics were used to prevent the infection, and proper bladder and bowel care was necessary. Every time there was a rat to die, it should be recorded. Until the 28th day after the transection, the survival proportions were drawn to exhibit the differences among four groups.
Functional Assessment
Every week after SCI was performed, hindlimb locomotor function was assessed according to the Basso-Beattie-Bresnahan (BBB) scale. [12] [13] The rats were placed in an open space of 90 cm Â 120 cm and allowed to walk freely for 5 min. Two observers who were blinded to the groups evaluated the locomotor function according to the 21-point BBB scale, with scores ranging from 0 (no hindlimb movement or weight support) to 21 (normal movement).
Evaluation of Hindlimb Muscle Atrophy
Twelve weeks after implantation, the bilateral gastrocnemius muscles were dissected. Their weight was measured to evaluate the muscular atrophy caused by central nerve denervation. The specimens of the muscle were embedded in paraffin wax and cut into 5-mm-thick transverse sections for Masson's trichrome staining. Then, the density and diameter of muscle fibers were calculated using an optical microscope (Carl Zeiss, Jena, Germany).
Histological and Immunohistochemical Evaluation and Microscopic Observation
Animals were euthanatized at 4, 10, and 12 weeks for histological and immunohistochemical evaluation. Parts of spinal cord from T7-11 were dissected carefully. Further, they were fixed in 4% (v/v) formaldehyde, embedded in paraffin wax, and cut into 5-mm-thick longitudinal sections. The specimens were stained with hematoxylin and eosin (H&E) to detect the structures . For the immunohistochemical analysis, the spinal cord sections were stained with primary antibodies against neurofilament-associated proteins (NF, Santa Cruz Biotechnology, Santa Cruz, CA), glial fibrillary acidic protein (GFAP, Santa Cruz Biotechnology, Santa Cruz, CA), and CD34 (Abcam, Cambridge, 
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MA). The stained sections were observed under a digital microscope camera (Zeiss, Germany) and imaged at 200Â and 400Â magnification. Since VEGF had a potential tumorigenesis, anomalous cells were also seeked in the images. In the immunohistochemical images, the percentage of positive area which included NF (GFAP or CD34) positive cells were chosen to calculated at 400Â magnification in each group at 12 weeks according to the Bioquant image analysis systems.
Microvessel Count
The anti-CD34-stained sections were observed at 40Â magnification. Focusing on the high vascular density areas, the CD34-positive microvascular endothelial cells were counted at 400Â magnification. All hyperchromatic vascular endothelial cells or endothelial cell clusters separated by connective tissue were regarded as a microvascular tissue (Weinder method).
14-15 Four specimens were counted in each group.
Statistical Analysis
All the data are presented as mean AE SEM. Statistical analysis was performed by two-tailed Student's t-test for single comparisons and One-way Analysis of Variance (ANOVA) for multi-group comparisons using the SPSS software (version 19.0, SPSS Inc., Chicago, IL). The percentage of positive area was calculated by the Bioquant image analysis systems (BIOQUANT Inc., Nashville, TN). The values were statistically significant at p < 0.05.
RESULTS

Survival Analysis of Experimental Animals
After spinal cord was transected completely, paralysis of the hindlimbs, sensory loss, and dysfunction of the bladder sphincter appeared. A daily intramuscular injection of penicillin was administered for three days, followed by a weekly injection. There were no urinary tract or other systemic infections.
On day 28th after the transection, the survival rate in the sham group was 100%, whereas it was 70% in the control group, 65% in the CS group, and 80% in the CS/CBD-VEGF group. The survival curve exhibited significant differences among the four groups (p < 0.05), but there were no differences of the survival trend between control, CS, and CS/CBD-VEGF group (p > 0.05) (Fig. 2) .
Effect of CS/CBD-VEGF Transplantation on Hindlimb Motor Function
The BBB scores were used to evaluate the movement of hindlimbs. In the sham group, the BBB scores were around 21 for 12 weeks. In the transaction groups, the BBB scores started with 0 and showed a trend of increase. A rapid functional recovery in the hindlimb locomotor function occurred in the first 6 weeks, but there were no significant differences between the control group, CS group, and CS/CBD-VEGF group (p > 0.05). Six weeks later, the increase of BBB scores in the control group and CS group reached a plateau, and the recovery of function in the CS/CBD-VEGF group was more accelerated than those of the other two groups. 12 weeks after the surgery, the BBB scores in the CS/CBD-VEGF group (left: 11.75 AE 0.96, n ¼ 4; right: 11.75 AE 0.5, n ¼ 4) were significantly higher than that that in the control group (left: 11.75 AE 0.5, n ¼ 4, p < 0.05; right: 9.17 AE 0.41, n ¼ 4, p < 0.05) and the CS group (left: 9.17 AE 0.41, n ¼ 4, p < 0.05; right: 10.25 AE 0.5, n ¼ 6, p < 0.05). Otherwise, the BBB scores displayed no significant differences between the left and right hindlimb in each of the groups . There were no significant difference between 11 weeks and 12 weeks on both hindlimbs in the control group (p > 0.05) (Fig. 3) .
Evaluation of Muscle Atrophy by Muscle Mass Analysis and Masson's Trichrome Staining
The gastrocnemius muscle manifested greater atrophy in the transection groups than in the sham group. At the tenth week after transection, the wet weight in the CS group (left: 1.63 AE 0.14g, n ¼ 4; right: 1.69 AE 0.13 g, n ¼ 4) and CS/CBD-VEGF group (left: 1.81 AE 0.11 g, n ¼ 4; right: 1.82 AE 0.12 g, n ¼ 4) were heavier than that in the control group (left: 1.37 AE 0.18, n ¼ 4, p < 0.05; right: 1.34 AE 0.22, n ¼ 4, p < 0.05), but there were no differences between the CS group and CS/CBD-VEGF group (p > 0.05) until the 12th week (Fig. 4) .
At the12th week, the density and diameter of the gastrocnemius muscle were measured by Masson's trichrome staining to evaluate the muscle atrophy. The CS/CBD-VEGF group had a greater density and larger diameter compared to the control group and CS group, and there were less connective tissue formation between muscle fibers, indicating a better recovery from muscle atrophy. The control group had the lowest values of density and diameter, which was consistent with the muscle weights ( Fig. 5A and B) .
Histological and Immunohistochemical Evaluation of Local Nerve and Vascular Regeneration
The results of HE staining indicated that the CS/CBD-VEGF group had better tissue regeneration than the 
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control and CS groups. The distal and proximal ends at the injury site were gradually connected in the CS group and CS/CBD-VEGF group. Otherwise, there were larger cavity formation and less nerve regeneration in the control group (Fig. 6) . After observing the images, there were no anomalous cells in all groups. At 4, 10, and 12 weeks post-implantation, the nerve regeneration was observed under a digital microscope camera (NF for axon fibers). More NF-positive neural fibers were present in the CS/CBD-VEGF group than in the control and CS groups, which indicated that there were more myelinated fibers regenerated (Fig. 7A) . Qualitatively, there were more NF-postive area in the CS/CBD-VEGF group than other surgical groups at 12 weeks (n ¼ 3, p 0.05), indicating greater axonal regeneration (Fig. 7B) . The immunostaining images revealed that the neural fibers extended through the scaffold in a well-ordered direction in the CS group and CS/CBD-VEGF group. The CD34-postive cells were stained to assess the formation of blood vessels. 16 The microvessel density in the CS/CBD-VEGF group was significantly higher than those in the other groups (n ¼ 3, p 0.05) (Fig. 8A and B) . The results of microvessel count showed that significantly more blood vessels had been formed in the CS/CBD-VEGF group than in the control and CS groups (n ¼ 4, p 0.05), but there was no difference between the control group and CS group (n ¼ 4, p > 0.05) (Fig. 9) .
The formation of glial scar was evaluated by the amount of GFAP þ astrocytes. At 4, 10, and 12 weeks after surgery, there were few GFAP þ astrocytes at the injury site in the CS/CBD-VEGF group (Fig. 10A) . At 12 weeks, GFAP þ astrocytes were more abundant in the control group than in the CS and CS/CBD-VEGF groups (n ¼ 3, p 0.05), indicating more pronounced glial scar formation (Fig. 10B) .
DISCUSSION
Collagen materials have been used as the ideal scaffolds for spinal cord repair. Due to collagen scaffold's excellent biocompatibility and low antigenicity, these 
17-18
It is conducive to cell adhesion, growth, proliferation, and differentiation and have good microstructure and certain mechanical strength. It can provide a delivery system for cytokines (bFGF, NT3, VEGF, etc.) and stem cells (OECs, MSCs, SCs, ESCs, etc.) without losing their biological efficiency. [19] [20] [21] Thus, a collagen scaffold (CS) was used to bridge the transected nerve stumps and sustain nerve regeneration. The results of previous studies showed that collagen scaffold implantation into the SCI site could promote nerve cell survival and neurite growth. 22 Furthermore, this scaffold type promoted nerve regeneration and functional recovery. 23 Reportedly, collagen scaffold facilitated the migration of native Schwann cells (SCs) into the site of the lesion and guided axon growth. 24 Vascular injury is one of the main mechanisms of spinal cord secondary injury in pathology. 25 The pathological and physiological changes include hemorrhage, microcirculation disturbance, and tissue ischemia-reperfusion injury. Some studies indicated that vascular injury was mainly concentrated in the gray matter due to its more abundant blood vessels. 26 According to the findings of a local blood flow 
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investigation, blood flow is decreased rapidly within hours after injury, especially in the gray matter. A short time later, an infarction of the white matter occurs gradually. [27] [28] Increased levels of VEGF were detected at spinal injury sites. 29 It can promote the proliferation and migration of vascular endothelial cells and increase the density of capillaries. 30 The newly formed blood vessels facilitate the outgrowth of neural fibers by providing sufficient nutrients and oxygen, 31 and a sufficient blood supply is crucial for the survival and regeneration of axons. By using MSCs or VEGF as individual therapies in repair of rat peripheral nerve defects, people found VEGF was superior to MSCs in facilitating nerve regeneration. 32 Beside the promotion of axonal regeneration, VEGF also protects the remaining motoneurons from apoptosis at the injury site. 33 Reportedly, VEGF-treated animals with brachial plexus palsy had less degeneration of the brachial plexus and a greater number of surviving motoneurons. 34 In our study, VEGF was optioned for the treatment of SCI because of its important role in capillary formation and axonal regeneration.
However, the half-life of VEGF is too short to maintain its local therapeutic efficacy. Previous studies revealed that CBD-VEGF binds specifically to collagen by collagen-binding domain (CBD). In an earlier examination, the combination of CBD-VEGF and CS retained a high local concentration at the injury site. Furthermore, the ability of this target delivery system to promote nerve regeneration in peripheral nervous system was confirmed. 10 In order to assess the effect of CS/CBD-VEGF delivery system central nervous system, we built a rat model of transected spinal cord injury. After the injury, all rats had symptoms of lower limb paralysis. Shortly after the operation, especially in the first 4 weeks, the rats manifested a high death rate in the surgical groups, but there were no differences between control, CS, and CS/CBD-VEGF group. The death may be caused by infection, urinary retention, blood loss, or pulmonary edema. The results of BBB score indicated that the degree of locomotor recovery in the CS/CBD-VEGF group was the highest, and the rats could stand up on their own lower limbs but had poor limb coordination. Central nervous system injuries may result in degeneration of target muscles, ultimately followed by muscle atrophy. The weight of gastrocnemius muscles and the density of myofibers in the CS/CBD-VEGF group were greater than those in the control and CS groups, indicating a more severe muscle atrophy. Similar findings have been obtained in other studies, indicating that the transplantation of CS loaded with other cytokines retarded the process of muscle atrophy and was beneficial to the recovery of neuronal function after the operation. [35] [36] The lack of contact guidance makes the processes of nerve regeneration at the spinal cord injury site disordered and blind, and crossing the injury zone, the axons can hardly reach the distal end. The formation of glial scar at the local site was an obstacle to the extension of the nerve. 37 As we expected, the regenerated nerve fibers extended in an ordered direction in the collagen scaffolds, and there were more ordered NF-positive nerve fibers at the injury site in the CS/CBD-VEGF group than in the control and CS groups. The largest area of CD34-positive cells was also found in the CS/CBD-VEGF group, indicating more pronounced capillary formation. In contrast, the processes of nerve and vessel growth were exceedingly limited in the control group, but there were more GFAP-positive astrocytes than in the other groups. This outcome might be associated with the glial scar inhibition in the regeneration and migration of nerve fibers, and the decreased accumulation of glial scars at the lesion site of the CS implantation group .As previously demonstrated, VEGF was associated with astrocytic and microglia activation around the site of spinal cord injury. 38 But in our study, there were no obvious differences of the percentage of GFAP-positive area between CS and CS/CBD-VEGF groups. So VEGF did not facilitate scar formation in study. From the immunohistochemical results, we concluded that the CS/CBD-VEGF delivery system might create a more suitable microenvironment at the injury site, providing the regenerating nerve with linear guidance and promoting capillary formation.
The delivery system with stable binding of VEGF improved the microenvironment, guided axon growth, and promoted neovascularization at the injury site.
The results of our study demonstrated the feasibility and effectiveness of the administration of the CS/CBD-VEGF system for the treatment of spinal cord injury. Ã p < 0.05.
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Therefore, the use of CS/CBD-VEGF may be practically feasible for the clinical treatment of spinal cord injury. Otherwise, the attempts to achieve nerve regeneration after injury by using single cytokines have shown limited functional recovery. Studies showed that the use of magnetic nanoparticles combined with nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) could strongly promote the regeneration process and the recovery of neurological function compared to that obtained with single factor. 39 Neural stem/progenitor cells (NSCs) which were transfected with VEGF may facilitate the recovery of motor and sensory function than simple NSCs, and it had a better therapeutic effectiveness. 40 For effective spinal cord repair after SCI, the implantation of collagen scaffolds loaded with stem cells and cytokines should be considered in the development of therapeutic strategies. 
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